JP2017523784A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523784A5
JP2017523784A5 JP2017505792A JP2017505792A JP2017523784A5 JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5 JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5
Authority
JP
Japan
Prior art keywords
seq
sequence shown
amino acid
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523784A (ja
JP6712261B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/042986 external-priority patent/WO2016022400A1/en
Publication of JP2017523784A publication Critical patent/JP2017523784A/ja
Publication of JP2017523784A5 publication Critical patent/JP2017523784A5/ja
Application granted granted Critical
Publication of JP6712261B2 publication Critical patent/JP6712261B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505792A 2014-08-04 2015-07-30 Ｗｔ−１に特異的なｔ細胞免疫治療 Expired - Fee Related JP6712261B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462033045P 2014-08-04 2014-08-04
US62/033,045 2014-08-04
US201562164783P 2015-05-21 2015-05-21
US62/164,783 2015-05-21
PCT/US2015/042986 WO2016022400A1 (en) 2014-08-04 2015-07-30 T cell immunotherapy specific for wt-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018142600A Division JP2018183175A (ja) 2014-08-04 2018-07-30 Ｗｔ−１に特異的なｔ細胞免疫治療

Publications (3)

Publication Number Publication Date
JP2017523784A JP2017523784A (ja) 2017-08-24
JP2017523784A5 true JP2017523784A5 (enExample) 2018-09-06
JP6712261B2 JP6712261B2 (ja) 2020-06-24

Family

ID=53901124

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017505792A Expired - Fee Related JP6712261B2 (ja) 2014-08-04 2015-07-30 Ｗｔ−１に特異的なｔ細胞免疫治療
JP2018142600A Pending JP2018183175A (ja) 2014-08-04 2018-07-30 Ｗｔ−１に特異的なｔ細胞免疫治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018142600A Pending JP2018183175A (ja) 2014-08-04 2018-07-30 Ｗｔ−１に特異的なｔ細胞免疫治療

Country Status (7)

Country Link
US (1) US10538572B2 (enExample)
EP (1) EP3177314B1 (enExample)
JP (2) JP6712261B2 (enExample)
CN (1) CN107074970B (enExample)
CA (1) CA2956545A1 (enExample)
ES (1) ES2841274T3 (enExample)
WO (1) WO2016022400A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6476182B2 (ja) 2013-11-22 2019-02-27 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改変された高親和性ヒトｔ細胞受容体
SG11201707182WA (en) * 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
IL308831A (en) 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
WO2018129270A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
US11603519B2 (en) * 2017-02-06 2023-03-14 National Cancer Center Japan T-cell receptor
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
US11725210B2 (en) 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
EA201992536A1 (ru) 2017-04-24 2020-03-05 Оспедале Сан Раффаэле С.Р.Л. Tcr и пептиды
CN111032686B (zh) * 2017-06-30 2024-05-14 莱顿大学医学中心附属莱顿教学医院 血液恶性肿瘤的治疗
NL2019156B1 (en) * 2017-06-30 2019-01-10 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Treatment of haematological malignancies
CN107267463A (zh) * 2017-08-23 2017-10-20 安徽惠恩生物科技股份有限公司 一种针对乳腺癌的Car‑NK细胞制备方法
JP7422069B2 (ja) 2017-09-19 2024-01-25 トロピック バイオサイエンシーズ ユーケー リミテッド 真核細胞において遺伝子発現をサイレンシングするための非コードｒｎａ分子の特異性の改変
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
US12280092B2 (en) 2018-01-05 2025-04-22 Nantbio, Inc. Reprogrammed T cell-like NK cells
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
CN112040986A (zh) 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
DE102018108612A1 (de) * 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
CN112566698A (zh) * 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
CN112585277A (zh) * 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020030631A1 (en) * 2018-08-06 2020-02-13 Medigene Immunotherapies Gmbh Ha-1 specific t cell receptors and their use
US20210317184A1 (en) * 2018-09-05 2021-10-14 GlaxoSmithKline Intellectual Property Devolopment Limited T cell modification
US12440546B2 (en) 2018-10-05 2025-10-14 International Institute Of Cancer Immunology, Inc. Composition for preventing or treating benign tumor
CA3116132A1 (en) 2018-10-16 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for immunotherapy
GB201817821D0 (en) * 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
BR112021017703A8 (pt) 2019-03-11 2023-04-18 Hutchinson Fred Cancer Res Receptores de células t wt1 de alta avidez e usos dos mesmos
CN111714618B (zh) * 2019-03-22 2024-07-12 香雪生命科学技术（广东）有限公司 T细胞和高亲和力pd-1融合蛋白的组合
EP3750547A1 (en) * 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
KR20220050176A (ko) * 2019-08-20 2022-04-22 프레드 헛친슨 켄서 리서치 센터 Wt-1에 특이적인 t-세포 면역요법
EP3786178A1 (en) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
EP4086281A4 (en) * 2019-12-30 2024-02-14 China Immunotech (Beijing) Biotechnology Co., Ltd IMPROVED STAR T CELL RECEPTOR AND ITS APPLICATION
US12686725B2 (en) 2020-05-05 2026-07-21 Mythic Therapeutics, Inc. Anti-DLL3 antibodies and methods of use
CN114106144B (zh) * 2020-08-27 2024-01-26 溧阳瑅赛生物医药有限公司 识别hla-a*02/wt1靶点的tcr及其应用
US20250032540A1 (en) 2020-12-14 2025-01-30 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US20250003951A1 (en) * 2021-04-21 2025-01-02 Oxford University Innovation Limited Method and composition
EP4340853A4 (en) * 2021-05-20 2025-05-07 Washington University Neuroprotective compositions and methods
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
CN113773378B (zh) * 2021-10-14 2023-11-03 深圳大学总医院 T细胞受体及其应用
CN118525037A (zh) * 2021-10-29 2024-08-20 侯亚非 识别ctnnb1中s37f突变的t细胞受体及其应用
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
WO2024038165A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
EP4609202A2 (en) * 2022-10-28 2025-09-03 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
CN121712794A (zh) 2023-06-29 2026-03-20 迪斯派奇生物治疗公司 合成细胞因子受体
WO2025240518A1 (en) 2024-05-14 2025-11-20 Dispatch Biotherapeutics, Inc. Modified lentiviral transfer plasmids
GB202406990D0 (en) * 2024-05-16 2024-07-03 Univ Oxford Innovation Ltd T cell receptors and uses thereof
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
EP1550453B1 (en) 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
US7575925B2 (en) 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
NZ702108A (en) * 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
NZ741124A (en) 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
PT2951202T (pt) * 2013-01-29 2020-07-07 Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch Moléculas de ligação de alta avidez que reconhecem mage-a1

Similar Documents

Publication Publication Date Title
JP7157839B2 (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
Johdi et al. Colorectal cancer immunotherapy: options and strategies
JP7223055B2 (ja) 癌治療のための併用免疫療法及びサイトカイン制御療法
Baxevanis et al. Cancer immunotherapy
Dotti et al. Design and development of therapies using chimeric antigen receptor‐expressing T cells
Zeltsman et al. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma
Redeker et al. Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination
JP2020509767A5 (enExample)
Kershaw et al. Gene-engineered T cells for cancer therapy
CN111989118B (zh) 包含耗竭性抗cd4单克隆抗体的抗癌t细胞治疗剂辅助用组合物及其用途
Bernatchez et al. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy
JP2016520074A5 (enExample)
WO2018193119A1 (en) Gene therapy
JP2017531687A5 (enExample)
WO2017159736A1 (ja) 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター
JP2018183175A (ja) Ｗｔ−１に特異的なｔ細胞免疫治療
JP2021512637A5 (enExample)
Zhang et al. Genetic engineering with T cell receptors
JP2020533962A5 (enExample)
JP2023524853A5 (enExample)
Danhof et al. CARs and other T cell therapies for MM: the clinical experience
JP2022525099A5 (enExample)
CN114555815B (zh) T细胞受体及其使用方法
Dhodapkar et al. Hematologic malignancies: plasma cell disorders
Brayer et al. Developing strategies in the immunotherapy of leukemias